<DOC>
	<DOC>NCT02714049</DOC>
	<brief_summary>Unblinded study of flibanserin for 8 weeks with responders randomized 1:1 to receive study medication alone vs. study medication and sex therapy for 12 additional weeks.</brief_summary>
	<brief_title>Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy</brief_title>
	<detailed_description>This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive flibanserin for an 8-week run-in period to differentiate between responders and non-responders. Responders will be determined by a score of 1-3 on the Patient Global Impression of Improvement (PGI-I) at 8 weeks from baseline, and will be randomized 1:1 to receive study medication alone vs. study medication and sex therapy for an additional 12 weeks.</detailed_description>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
	<criteria>1. Subject is willing and able to provide written informed consent and HIPAA authorization before any study procedures are conducted; 2. Subject is female; 3. Subject is ≥18 years old; 4. Subject has biologicbased HSDD as her primary sexual complaint; 5. Subject scores &lt;26 on FSFI and &lt;4.8 on desire domain of FSFI at screening; 6. Subject scores &gt;18 on FSDSDAO; 7. Subject answers yes to questions 14 on the DSDS screener; 8. Subject is willing to use effective contraception during the study if premenopausal (oral contraceptives, barrier method, long acting reversible contraceptive, surgical sterilization); 9. Subject agrees to comply with the study procedures and visits. 1. Subject has sexual pain; 2. Subject does not have generalized, acquired HSDD; 3. Subject has used flibanserin in the last 6 months; 4. Subject has history of alcohol or drug abuse; 5. Subject uses tobacco in any form; 6. Subject is currently using androgen therapy and unwilling to washout; 7. Subject is pregnant, nursing, or planning to become pregnant over the next 6 months; 8. Subject is taking a moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitor; 9. Subject is taking a CYP3A4 inducer; 10. Pglycoprotein substrate; 11. Subject has a history of liver impairment; 12. Subject has any chronic medical condition or psychologic disorder that the Principal Investigator feels makes her ineligible for the study; 13. Subject has any condition or exhibits behavior that indicates to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hypoactive sexual desire disorder</keyword>
	<keyword>Addyi</keyword>
	<keyword>flibanserin</keyword>
	<keyword>low sexual desire</keyword>
	<keyword>HSDD</keyword>
</DOC>